Hypoadiponectinemia and Insulin Resistance are Associated with Nonalcoholic Fatty Liver Disease

Yoon, Dokyoung; Lee, Seung Hwan; Park, Hye Soon; Lee, Jihoon; Park, Jin Seo; Cho, Kyung Hwan; Kim, Seon Mee

doi:10.3346/jkms.2005.20.3.421

Cited by 34 publications

(26 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 In this study, we observed that treatment with candesartan, an angiotensin-II receptor antagonist, was associated with a significantly decreased liver weight and ratio of liver weight to body weight, in addition to reduced lipid infiltration in the liver, reported the beneficial effect of the angiotensin receptor blocker in seven subjects with non-alcoholic steatohepatitis and hypertension. Histological assessment showed improvement of hepatic necro-inflammation in five patients, reduction of hepatic fibrosis in four individuals, and disappearance of iron deposition in two subjects.…”

Section: Discussionmentioning

confidence: 80%

“…14 In the present investigation, we found that serum adiponectin concentrations and hepatic expression levels of adiponectin mRNA were significantly higher in candesartan-treated mice than in control mice, suggesting that the angiotensin receptor blocker might alleviate NAFL through the increase of circulating adiponectin levels. Serum adiponectin levels are reduced under conditions of insulin resistance such as NAFL, 12 despite an elevated mass of fat cells. Delivery of recombinant adiponectin into mice with NAFL or alcoholic fatty liver has been shown dramatically to alleviate hepatomegaly and steatosis and to significantly attenuate inflammation and the increased levels of serum alanine aminotransferase.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Angiotensin-II Receptor Antagonist Alleviates Non-alcoholic Fatty Liver in KKAy Obese Mice with Type 2 Diabetes

Takahashi

Moriya

et al. 2006

J Int Med Res

View full text Add to dashboard Cite

We examined the effects of the angiotensin-II receptor antagonist candesartan on non-alcoholic fatty liver (NAFL) and circulating adiponectin concentrations in KKAy obese mice with type 2 diabetes mellitus. The KKAy mice were randomly assigned to receive either candesartan at a once-daily dose of 10 mg/kg (n = 5) or placebo (n = 5). The differences in liver weight, histological evaluation of hepatic lipid infiltration, serum adiponectin concentration and hepatic adiponectin mRNA levels between the two groups were determined on day 7 after treatment was initiated. Candesartan-treated mice demonstrated significantly lower liver weights and reduced lipid droplets in hepatic cells compared with control mice. The circulating adiponectin levels and hepatic expression of adiponectin mRNA were significantly higher in candesartan-treated mice than control mice. These results suggest that candesartan might alleviate NAFL through elevation of circulating adiponectin levels in KKAy obese mice with type 2 diabetes mellitus.

show abstract

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Angiotensin-II Receptor Antagonist Alleviates Non-alcoholic Fatty Liver in KKAy Obese Mice with Type 2 Diabetes

Takahashi

Moriya

et al. 2006

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…[41][42][43] This association has remained significant in some 39,40 but not all studies after adjusting for BMI 38,43 or BMI and other risk factors. 44 In a study of 271 nondiabetic subjects in whom liver fat was measured by proton spectros- Figure 1. Reproduced with permission from Kotronen et al 25 copy, the correlations between liver fat and BMI, waist circumference, and intraabdominal fat were 0.47, 0.58, and 0.65, respectively (PϽ0.0001 for all).…”

Section: Waistmentioning

confidence: 99%

Fatty Liver

Kotronen

Yki‐Järvinen

2008

ATVB

708

264

View full text Add to dashboard Cite

Abstract-Although the epidemic of obesity has been accompanied by an increase in the prevalence of the metabolic syndrome, not all obese develop the syndrome and even lean individuals can be insulin resistant. Both lean and obese insulin resistant individuals have an excess of fat in the liver which is not attributable to alcohol or other known causes of liver disease, a condition defined as nonalcoholic fatty liver disease (NAFLD) by gastroenterologists. The fatty liver is insulin resistant. Liver fat is highly significantly and linearly correlated with all components of the metabolic syndrome independent of obesity. Overproduction of glucose, VLDL, CRP, and coagulation factors by the fatty liver could contribute to the excess risk of cardiovascular disease associated with the metabolic syndrome and NAFLD. Both of the latter conditions also increase the risk of type 2 diabetes and advanced liver disease. The reason why some deposit fat in the liver whereas others do not is poorly understood.

show abstract

“…Another study in Taiwan, including 210 obese subjects, also demonstrated similar association between WC and fatty liver (multivariate logistic regression analysis, per 1-cm increase in WC, OR 1.10, 95% CI 1.04-1.16) [13] . A Korean study with 91 cases also found association between WC and NAFLD (per 1-cm increase in WC, OR 1.13, 95% CI 1.04-1.22) [14] . A Japanese study (n=129 individuals) reported an increase of WC increased with the severity of fatty liver [15] .…”

Section: Discussionmentioning

confidence: 87%

The Association of non-alcoholic Fatty Liver Disease with Body Mass Index and Waist Circumference in a Chinese population

2018

J Adv Nutr Hum Metab

View full text Add to dashboard Cite

Introduction: Non-alcoholic fatty liver disease (NAFLD) often occurs together with obesity. Body mass index (BMI) and waist circumference (WC) are two important physical parameters of obesity. Here we analyzed in a Chinese population the statistical relationship between NAFLD and these two obese parameters. Methods: Data were collected retrospectively from the Taichung Verteran General Hospital during a three-year period from January 2007 to December 2009. Exclusion criteria included large consumption of alcohol and chronic hepatitis (B and C). Patients first went through liver ultrasound scanning and then were assigned to either the normal or fatty liver group. Patients were also subgrouped as either overweight/obesity (BMI≧25 mg/m2) or normal weight; central obesity (waist circumference ≧ 90 cm for men and ≧ 80 cm for women) or normal. The statistical association with NAFLD was then compared for each subgroup. Results: A total of 916 patients (24.3%) were classified into the fatty liver group and 2868 patients (75.8%) were classified into the normal group. The ratios of overweight/obesity (59.0% vs. 49.4%, P=0.001) and central obesity (18.4% vs. 15.7%, P=0.006) were significantly higher in the fatty liver group compared with the normal. The positive association with NAFLD was significant in overweight/obesity (OR 1.46, 95% CI 1.33 to 1.73), but insignificant in central obesity (OR 1.29, 95% CI 0.83 to 2.03). After further stratification, significant positive association was found in patients with both higher BMI and WC (OR 2.09, 95% CI 1.39 to 3.80) and higher BMI but normal WC (OR 1.42, 95% CI 1.17 to 1.73). But such association was not found in those with higher WC but normal BMI (OR 1.05, 95% CI 0.60 to 1.84). Conclusion: BMI, and not WC, had a strong positive association with NAFLD. Patients with higher BMI and higher WC had additional risk for NAFLD.

show abstract

Hypoadiponectinemia and Insulin Resistance are Associated with Nonalcoholic Fatty Liver Disease

Cited by 34 publications

References 42 publications

Angiotensin-II Receptor Antagonist Alleviates Non-alcoholic Fatty Liver in KKAy Obese Mice with Type 2 Diabetes

Angiotensin-II Receptor Antagonist Alleviates Non-alcoholic Fatty Liver in KKAy Obese Mice with Type 2 Diabetes

Fatty Liver

The Association of non-alcoholic Fatty Liver Disease with Body Mass Index and Waist Circumference in a Chinese population

Contact Info

Product

Resources

About